Table 2.
Characteristics of the patients with andomized SLN mapping (n = 139), with and without Sentinel Lymph Node (SLN) metastasis.
| Characteristics | Sentinel Lymph Node Positive 1 (n = 20) | Sentinel Lymph Node Negative (n = 119) | p-Value |
|---|---|---|---|
| Age | 0.041 | ||
| <60 years | 3 (15%) | 46 (39%) | |
| ≥60 years | 17 (85%) | 73 (61%) | |
| BMI | 0.619 | ||
| <25 | 5 (25%) | 25 (21%) | |
| ≥25 | 15 (75%) | 94 (79%) | |
| Pre-operative CA-125 | 0.346 | ||
| <35 U/mL | 14 (70%) | 94 (79%) | |
| ≥35 U/mL | 6 (30%) | 19 (16%) | |
| Unknown | 0 | 6 (5%) | |
| Pre-operative histological grade | 0.595 | ||
| Grade 1 | 14 (70%) | 90 (76%) | |
| Grade 2 | 6 (30%) | 29 (24%) | |
| Postoperative histological grade | <0.001 | ||
| Grade 1 | 9 (45%) | 95 (80%) | |
| Grade 2 | 5 (25%) | 23 (19%) | |
| Grade 3 | 4 (20%) | 1 (1%) | |
| Non-endometrioid | 2 (10%) | 0 | |
| Tumor size | 0.566 | ||
| <20 mm | 6 (30%) | 34 (29%) | |
| ≥20 mm | 12 (60%) | 68 (57%) | |
| Unknown | 2 (10%) | 17 (14%) | |
| Myometrial invasion | 0.004 | ||
| None | 1 (5%) | 26 (22%) | |
| <50% | 5 (25%) | 55 (46%) | |
| ≥50% | 14 (70%) | 38 (32%) | |
| Lymphovascular space invasion | <0.001 | ||
| Present | 11 (55%) | 15 (13%) | |
| Absent | 7 (35%) | 102 (86%) | |
| Unknown | 2 (10%) | 2 (1%) | |
| ER/PR status 2 | n/a | ||
| Both positive | 14 (70%) | 50 (42%) | |
| Both negative | 1 (5%) | 0 | |
| ER pos/PR neg | 4 (20%) | 3 (3%) | |
| ER/PR unknown | 1 (5%) | 66 (55%) |
1 Includes macro-metastases (n = 10), micro-metastasis (n = 7) and isolated tumor cells (n = 3). 2 ER: estrogen receptor, PR: progesterone receptor, NB: a SLN was detected by the pathologist in 139 of 152 patients.